<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pliant Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/pliant-therapeutics-inc</link>
<description>Latest news and press releases for Pliant Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pliant-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ae2078dffbe2df10eb52.webp</url>
<title>Pliant Therapeutics, Inc.</title>
<link>https://6ix.com/company/pliant-therapeutics-inc</link>
</image>
<item>
<title>Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference</guid>
<pubDate>Wed, 06 May 2026 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Keith Cummings, M.D., Pliant’s Chief Financial Officer, will participate in a fireside chat on Tuesday, May</description>
</item>
<item>
<title>Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors</guid>
<pubDate>Thu, 30 Apr 2026 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1. “We are pleased to announce this m</description>
</item>
<item>
<title>Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Sat, 18 Apr 2026 17:31:00 GMT</pubDate>
<description>Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif., April 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in</description>
</item>
<item>
<title>Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Selected for oral presentation at Clinical Trials Mini Symposium SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.</description>
</item>
<item>
<title>Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2025-financial-results-7</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2025-financial-results-7</guid>
<pubDate>Wed, 11 Mar 2026 20:05:00 GMT</pubDate>
<description>PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 20</description>
</item>
<item>
<title>Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-to-participate-in-the-oppenheimer-healthcare-life-science-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-to-participate-in-the-oppenheimer-healthcare-life-science-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the</description>
</item>
<item>
<title>Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/enhanced-genomics-appoints-dr-katerina-leftheris-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/enhanced-genomics-appoints-dr-katerina-leftheris-to-its-board-of-directors</guid>
<pubDate>Fri, 09 Jan 2026 14:10:00 GMT</pubDate>
<description>CAMBRIDGE, England, January 09, 2026--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.</description>
</item>
<item>
<title>Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-interim-data-123000032</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-interim-data-123000032</guid>
<pubDate>Thu, 04 Dec 2025 12:30:00 GMT</pubDate>
<description>One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation of a Phase 1b expansion trial in 2026 Strong cash position supports planned operations through 2028 SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced in</description>
</item>
<item>
<title>Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-participate-piper-sandler-133000003</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-participate-piper-sandler-133000003</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025.Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will par</description>
</item>
<item>
<title>Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-210500604</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-210500604</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported third quarter 2025 financial results. “During the third quarter, our team continued to a</description>
</item>
<item>
<title>Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-200500575</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-200500575</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results. “While our activities in</description>
</item>
<item>
<title>Pliant Therapeutics Provides Update on BEACON-IPF</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-beacon-ipf-200500910</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-beacon-ipf-200500910</guid>
<pubDate>Fri, 27 Jun 2025 20:05:00 GMT</pubDate>
<description>Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial</description>
</item>
<item>
<title>Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-presents-clinical-preclinical-200300357</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-presents-clinical-preclinical-200300357</guid>
<pubDate>Wed, 21 May 2025 20:03:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., D</description>
</item>
<item>
<title>Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-200500662</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-200500662</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic disea</description>
</item>
<item>
<title>Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-strategic-realignment-200500028</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-strategic-realignment-200500028</guid>
<pubDate>Thu, 01 May 2025 20:05:00 GMT</pubDate>
<description>- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to su</description>
</item>
<item>
<title>Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-upcoming-presentations-200500361</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-upcoming-presentations-200500361</guid>
<pubDate>Mon, 07 Apr 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025. The following abstracts are posted on ATS 2025’s online itinerary planner for registered users. Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Sym</description>
</item>
<item>
<title>Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-interim-phase-120000529</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-announces-interim-phase-120000529</guid>
<pubDate>Mon, 17 Mar 2025 12:00:00 GMT</pubDate>
<description>Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination wi</description>
</item>
<item>
<title>Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-adopts-limited-duration-112000796</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-adopts-limited-duration-112000796</guid>
<pubDate>Thu, 13 Mar 2025 11:20:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to ga</description>
</item>
<item>
<title>Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-210500460</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-corporate-reports-210500460</guid>
<pubDate>Mon, 03 Mar 2025 21:05:00 GMT</pubDate>
<description>Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discont</description>
</item>
<item>
<title>Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-beacon-ipf-142700044</link>
<guid isPermaLink="true">https://6ix.com/company/pliant-therapeutics-inc/news/pliant-therapeutics-provides-beacon-ipf-142700044</guid>
<pubDate>Mon, 03 Mar 2025 14:27:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-relate</description>
</item>
</channel>
</rss>